NEPHROCARE HEALTH SERV L (NEPHROPLUS) Share Price Falls 5.13% Today
- September 24, 2026
- Posted by: Harsh Piplani
- Category: News
NEPHROPLUS Share Price fell to Rs 705 on 24 September 2026, down 5.13% from the previous close, while the company’s market capitalisation stood at Rs 7,534.89 crore. The move makes NEPHROCARE HEALTH SERV L a notable item in today’s stock news, especially because the supplied data confirms the price event but does not establish a company-specific catalyst. The stock opened at Rs 717.65, touched an intraday high of Rs 719.65 and a low of Rs 703, placing the day’s range close to the lower end of the session. Univest notes the fall in the NEPHROPLUS Share Price alongside valuation, sector and peer context, which together help frame the day’s decline without adding any unsupported reason.
From today’s facts, the NEPHROPLUS Share Price news is best read as a price-action event first and a fundamental comparison second. The stock’s valuation remains elevated versus the healthcare industry median, while its profitability ratios sit below some listed peers. That combination is why the share price fall is drawing attention in market commentary.
NEPHROCARE HEALTH SERV L (NEPHROPLUS) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 705 |
| Previous Close | Rs 743.1 |
| Today's Move | -Rs 38.10 (-5.13%) |
| Open | Rs 717.65 |
| High | Rs 719.65 |
| Low | Rs 703 |
| Turnover | Rs 33.53 crore |
| Market Capitalisation | Rs 7,534.89 crore |
| Market Cap Category | Mid Cap |
NEPHROPLUS Share Price Today reflected a clear single-session decline. The stock last traded at Rs 705, compared with the previous close of Rs 743.1, a fall of Rs 38.1 or 5.13%. It opened at Rs 717.65, traded up to Rs 719.65 and slipped to an intraday low of Rs 703, which means the close was near the lower end of the day’s range. That pattern shows where the NEPHROPLUS Share Price finished relative to the session’s opening and early trade, without extending the data beyond what is supplied.
Turnover stood at Rs 33.53 crore. On the company-size side, the stock sits in the Mid Cap category and the market cap was Rs 7,534.89 crore. For readers following NEPHROPLUS Share Price Live or NEPHROPLUS Share Price Update searches, the important point is simple: today’s move was decisive, but the workflow data does not identify a company-specific reason. In other words, NEPHROPLUS Stock News today is defined by the price event itself and the surrounding financial context. Investors watching NEPHROPLUS Share Price News can next track whether the stock stabilises around today’s low or continues to trade below the previous close.
NEPHROCARE HEALTH SERV L (NEPHROPLUS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 7,534.89 crore |
| P/E Ratio | 97.25x |
| P/B Ratio | 6.59x |
| ROE | 9.22% |
| ROCE | 16.18% |
| EPS | Rs 7.64 |
| Book Value Per Share | Rs 112.78 |
| Dividend Yield | 0% |
EPS is Rs 7.64 and book value is Rs 112.78 per share, both of which help anchor NEPHROPLUS Fundamental Analysis in per-share terms. Dividend yield is 0, so the current data does not show a cash dividend yield. In the context of NEPHROPLUS Financial Results and NEPHROPLUS Company News searches, the key takeaway is that today’s NEPHROPLUS Share Price fall happened against a backdrop of rich valuation and moderate profitability rather than a weak standalone operating profile. Univest readers often use this section to separate a price move from the underlying business metrics, and that distinction matters here.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Hospital & Healthcare Services |
| Benchmark Scope | same industry |
| Company P/E Ratio | 97.25x |
| Benchmark Median P/E | 48.15x |
| Benchmark Average P/E | 102.87x |
| Benchmark P/E Range | 6.91x to 1,616.57x |
| Company P/B Ratio | 6.59x |
| Benchmark Median P/B | 3.99x |
| Benchmark Average P/B | 4.81x |
| Company ROE | 9.22% |
| Benchmark Median ROE | 13.01% |
| Benchmark Average ROE | 13.23% |
| Company ROCE | 16.18% |
| Benchmark Median ROCE | 15.84% |
| Benchmark Average ROCE | 3.06% |
| Company Market Capitalisation | Rs 7,534.89 crore |
| Benchmark Median Market Cap | Rs 553.23 crore |
| Benchmark Average Market Cap | Rs 11,671.88 crore |
NEPHROPLUS operates in Healthcare, within the Hospital & Healthcare Services industry, and the benchmark scope covers the same industry with 65 companies. The company’s P/E of 97.25 is above the benchmark median of 48.15 and above the benchmark average of 102.87 only in relation to the broader range, where the maximum reaches 1,616.57 and the minimum is 6.91. Its P/B of 6.59 is above the benchmark median of 3.99 and above the benchmark average of 4.81. ROE at 9.22% is below the benchmark median of 13.01%, while ROCE at 16.18% is slightly above the benchmark median of 15.84%.
The market-cap benchmark also provides useful context. NEPHROPLUS market capitalisation of Rs 7,534.89 crore is above the industry median market cap of Rs 553.23 crore and below the industry average of Rs 11,671.88 crore. That places NEPHROPLUS in the upper part of the company-size distribution without suggesting anything about quality on its own. In NEPHROPLUS Stock Analysis and NEPHROPLUS Stock Performance searches, this sector view matters because the company is not priced like a plain lower-multiple healthcare name. Instead, today’s decline sits inside a segment where pricing, returns and market cap vary widely across listed peers.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise | APOLLOHOSP | 1,27,792.21 | 62.35 | 13.45 | 23.54 | 21.73 |
| Max Healthcare Institute | MAXHEALTH | 1,03,068.69 | 70.32 | 9.37 | 14.53 | 14.97 |
| MANIPAL HEALTH ENTERPRI L | MANIPALHOS | 98,160.02 | 112.09 | 5.48 | 12.95 | 13.93 |
| Fortis Healthcare | FORTIS | 67,512.13 | 64.19 | 6.62 | 11.32 | 14.07 |
| Aster DM Healthcare | ASTERDM | 65,493.11 | 208.03 | 15.67 | 13.07 | 16.22 |
NEPHROPLUS Share Price can also be read against listed hospital and healthcare service peers supplied in the dataset. Apollo Hospitals Enterprise trades at a P/E of 62.35, P/B of 13.45, ROE of 23.54% and ROCE of 21.73%, with market cap of Rs 1,27,792.21 crore. Max Healthcare Institute shows a P/E of 70.32, P/B of 9.37, ROE of 14.53% and ROCE of 14.97%, while Fortis Healthcare reports 64.19 times earnings, 6.62 times book and ROE of 11.32%.
Against those names, NEPHROPLUS’s P/E of 97.25 is higher than Apollo, Max Healthcare and Fortis, while its P/B of 6.59 is lower than Apollo and Max Healthcare, but close to Fortis. Its ROE of 9.22% is below the three peers mentioned, and ROCE of 16.18% is above Max Healthcare and Fortis but below Apollo. In short, NEPHROPLUS Share Price Today should be viewed with a peer lens: the stock’s valuation sits above several comparable healthcare names, while return ratios show a mixed position. That is useful for anyone tracking NEPHROPLUS Stock News or NEPHROPLUS Latest News through a comparative market frame.
Why Investors Are Watching NEPHROPLUS
- NEPHROPLUS Share Price fell 5.13% today, with the stock closing at Rs 705 versus a previous close of Rs 743.1.
- The day’s range was Rs 703 to Rs 719.65 after an open of Rs 717.65.
- Turnover was Rs 33.53 crore and market capitalisation stood at Rs 7,534.89 crore.
- The stock’s P/E of 97.25 is above the healthcare industry median P/E of 48.15.
- ROE is 9.22% and ROCE is 16.18%, compared with the same-industry benchmark medians of 13.01% and 15.84%.
About NEPHROCARE HEALTH SERV L
NEPHROCARE HEALTH SERV L operates in Healthcare and the Hospital & Healthcare Services industry. The supplied company data identifies it through the NEPHROPLUS symbol and places it within a benchmark set of listed healthcare peers. The visible profile in this article focuses on market capitalisation, valuation and return ratios because those are the verified fields supplied for NEPHROPLUS Share Price analysis. For readers scanning NEPHROPLUS Share News or NEPHROPLUS Company News, the core context is that this is a listed healthcare services company with a market cap of Rs 7,534.89 crore and a valuation profile that can be compared against the broader industry set.
Track NEPHROPLUS Share Price on Univest
Use NEPHROCARE HEALTH SERV L (NEPHROPLUS) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Readers can track NEPHROPLUS Share Price on Univest for live updates, valuation ratios, market capitalisation, shareholding pattern, 52-week levels and company insights in one place. Univest also brings together NEPHROPLUS Stock News, NEPHROPLUS Share Price Today and comparison data so the move can be followed with context.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did NEPHROPLUS Share Price fall today?
Ans. The supplied data shows NEPHROPLUS Share Price fell 5.13% to Rs 705, but it does not establish a company-specific catalyst. The move is visible in the open, high, low and close data for today’s session.
What is NEPHROPLUS Share Price Today?
Ans. NEPHROPLUS Share Price Today is Rs 705, compared with the previous close of Rs 743.1. The stock also opened at Rs 717.65 and traded between Rs 703 and Rs 719.65 during the session.
What is NEPHROPLUS market capitalisation?
Ans. NEPHROPLUS market capitalisation is Rs 7,534.89 crore. The stock is classified as Mid Cap in the supplied data, which is useful company-size context when reading today’s share price fall and valuation metrics.
How does NEPHROPLUS valuation compare with the industry?
Ans. NEPHROPLUS trades at a P/E of 97.25 and P/B of 6.59. Both are above the healthcare industry medians of 48.15 and 3.99, so the stock sits at a richer valuation than the benchmark set.
What do NEPHROPLUS ROE and ROCE show?
Ans. NEPHROPLUS reports ROE of 9.22% and ROCE of 16.18%. ROE is below the industry median of 13.01%, while ROCE is slightly above the industry median of 15.84% in the same benchmark group.
